Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis

​

Ponce, Puerto Rico and Los Angeles, CA - March 17, 2026 -  Sur180 Therapeutics and Nura Health today announced a strategic research collaboration, approved by the Boards of both companies, designed to integrate non-invasive precision diagnostics with next-generation non-hormonal therapeutics for endometriosis.

​

Endometriosis affects more than 1 in 10 women of reproductive age globally, and diagnosis often takes 7–10 years, delaying access to appropriate treatment and prolonging suffering. For many patients, the condition goes far beyond a painful period — affecting work, relationships, and mental health every single day. This partnership brings together two complementary scientific strengths to accelerate solutions for earlier detection and biologically targeted treatment.

​

Under this agreement, Sur180 and Nura Health will coordinate research workflows, data-sharing, biomarker analytics, and exploratory clinical activities aimed at improving diagnostic accuracy and guiding treatment selection. The collaboration supports each company’s independently developed technologies, creating a unified framework where diagnostic insights and therapeutic innovation reinforce one another and enable optimized care delivery through precision medicine.

​

“This collaboration creates a bridge between precision diagnostics and targeted therapeutic development, allowing us to move from risk stratification and early detection to biologically informed treatment strategies,” said Idhaliz Flores, Ph.D., Co-Founder & Chair of the Scientific Board at Sur180 Therapeutics and Chief Scientific Officer at Nura Health. “At a moment when endometriosis care is shifting toward personalized medicine, aligning diagnostic insights with therapeutic innovation is both timely and transformative.”

​

Nura Health brings a robust multi-modal biomarker signature, deep patient subtyping & phenotyping, and precision diagnostic platform integration, while Sur180 Therapeutics contributes translational therapeutic development grounded in molecular mechanisms and preclinical evidence using novel, non-hormonal targets that have demonstrated significant benefit in reducing endometriosis lesion size and inflammation. Co-Founder & CEO of Nura Health, Varun Kapoor, MD, emphasized the unique value of combining both teams’ expertise: “Together, we can align biological insights with targeted interventions, accelerating both rapid diagnosis and a more precise and responsive model of care for endometriosis patients that better addresses the complex disease burden across millions of affected women.”

​

By integrating biomarker discovery, clinical subtyping analytics, real-world data, and emerging therapeutic pathways, the partnership aims to break away from the traditional symptom-based approach. This unified effort supports a future standard of precision care defined by earlier detection, risk-informed follow-up, and mechanism-driven treatment selection.

​

About Sur180 Therapeutics

​

Sur180 Therapeutics is a women-centered biotechnology company developing non-hormonal therapeutics for endometriosis. With a majority Puerto Rican team and research conducted primarily from Ponce, Puerto Rico, Sur180 is built on more than 20 years of translational research. The company targets the stress-response pathway (CRHR1) to provide long-term pain relief without hormone suppression. Sur180 has secured a competitive, peer-reviewed grant from the National Institutes of Health (NIH) to advance its novel therapeutic approach and maintains active preclinical and translational research programs.

​

About Nura Health

​

Nura Health is a precision diagnostics company developing breakthrough non-invasive diagnostic tests and digital platform tools for women’s health. Through multiomic biomarker discovery, disease stratification, and AI-driven clinical platforms, Nura delivers actionable insights that support rapid diagnosis, longitudinal patient monitoring, and personalized care pathways, enabling expedited management of endometriosis, systemic complications, and associated inflammatory & metabolic conditions. Nura Health is supported by funding from the Advanced Research Projects Agency for Health (ARPA-H), strengthening its mission to accelerate high-impact diagnostic innovations that accelerate end-to-end care for millions of women.